Moderna’s New mNexspike Covid Shot Pulled Into GSK Patent Suit

Moderna Inc.'s mNexspike family of Covid-19 shots has joined SpikeVax as a target of GSK Plc’s lawsuit seeking royalties for alleged infringement of patented mRNA vaccine-delivery technology.

Two GSK units—GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC—filed an amended complaint Thursday with the approval of Judge Gregory B. Williams in the US District Court for the District of Delaware. Moderna has already “reaped billions of dollars” from SpikeVax without a license and continues to profit from the disputed technology, GSK wrote.

GSK also broadened its claims to cover components made in the US and shipped abroad for vaccine production.

Last October, GSK ...